Alpha Teknova (NASDAQ:TKNO – Get Rating) released its earnings results on Wednesday. The company reported ($0.47) EPS for the quarter, reports. The firm had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $7.90 million. Alpha Teknova had a negative net margin of 86.67% and a negative return on equity of 16.09%. Alpha Teknova updated its FY 2023 guidance to EPS.
Alpha Teknova Stock Performance
NASDAQ:TKNO traded down $0.13 during mid-day trading on Friday, hitting $3.21. 47,467 shares of the company traded hands, compared to its average volume of 47,282. The stock’s fifty day moving average price is $5.44 and its 200-day moving average price is $4.75. Alpha Teknova has a one year low of $3.02 and a one year high of $17.60. The company has a quick ratio of 4.85, a current ratio of 5.68 and a debt-to-equity ratio of 0.15. The firm has a market cap of $90.17 million, a price-to-earnings ratio of -2.47 and a beta of 0.33.
Institutional Trading of Alpha Teknova
Several hedge funds have recently bought and sold shares of TKNO. Strs Ohio lifted its position in shares of Alpha Teknova by 418.8% in the third quarter. Strs Ohio now owns 8,300 shares of the company’s stock worth $27,000 after buying an additional 6,700 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Alpha Teknova in the third quarter worth about $36,000. Tower Research Capital LLC TRC lifted its position in shares of Alpha Teknova by 825.7% in the third quarter. Tower Research Capital LLC TRC now owns 12,154 shares of the company’s stock worth $40,000 after buying an additional 10,841 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Alpha Teknova by 27.9% in the first quarter. JPMorgan Chase & Co. now owns 6,571 shares of the company’s stock worth $91,000 after buying an additional 1,435 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Alpha Teknova by 21.6% during the second quarter. Goldman Sachs Group Inc. now owns 12,806 shares of the company’s stock worth $108,000 after acquiring an additional 2,279 shares during the last quarter. Institutional investors own 22.74% of the company’s stock.
Alpha Teknova Company Profile
Alpha Teknova, Inc provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
- Get a free copy of the StockNews.com research report on Alpha Teknova (TKNO)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.